The Path to Sustainable Future
Oceanix Biotechnology Corporation is a leading, innovative Canadian biotechnology and biopharmaceuticals company actively engaged in the global marine biotechnology & biopharmaceuticals industry and is the world’s largest producer – one of three globally and the only one in Canada - of sustainable Keyhole Limpet Hemocyanin (KLH) and KLH proteins for the global anti-cancer vaccine and immunotherapy markets.
​​
The Company explores the diversity found in Canadian and global marine eco-systems to develop and market new biomedical, nutraceutical and food products and technologies that can only be derived from the unique forms, structures, physiology and chemistry found in marine organisms.
Better for Humans, Better for the the Planet
Oceanix Biotechnology is actively involved in the prospecting of oceanic and marine environments for novel sources and supplies of oceanic & marine biomass, for potential biopharmaceuticals and pharmaceutical compounds along with the perspective of sustainable aquaculture of marine organisms and the research, development and commercialization of novel pharmaceuticals, bio-pharmaceuticals, nutraceuticals and OTC products from ecologically stable and sustainable marine and ocean bio-resources (biomass).
Innovation - Driven Solutions
Revolutionizing Immunotherapy Developments
and Treatments
Powering Green and Blue
Innovations In Marine Research And Development For A Healthier Tomorrow.
Strong Social and Environmental Conscience
In Marine Culture, Research And Cultivation.
Milestones
Group
Oceanix is a subsidiary of Canadian-owned, Canagen Pharmaceuticals Inc. and Bage Biotechnology Co., Ltd.
​
Canagen is a well-established and innovative multinational pharmaceuticals company actively engaged in the manufacture of finished dosage, generic pharmaceuticals, active pharmaceutical ingredients (APIs) and OTC products and in the research, development and commercialization of novel drugs covering the cardiovascular, oncology, dementia and anti-viral therapeutic areas.
​
Canagen’s Nutraceuticals Division is actively involved in the research, development and commercialization of innovative nutraceutical products, utilizing best pharmaceuticals practices. Canagen owns and operates ten certified GMP pharmaceuticals factories in Canada, China, India and Russia and has dedicated R&D facilities in Canada, India and China.
​
The Company, through its wholly-owned Illumination Biotechnology Co., Ltd. subsidiary, is the world’s largest and leading manufacturer of Chaga mushroom extracts. Its ChagaPURE® brand of 100% Wild, Full-spectrum, Standardized Siberian and Canadian Chaga Mushroom extracts is globally recognized for its exceptional quality and potency as a result of its innovative process technology developed in collaboration with the National Research Council (NRC), the Canadian Government’s preeminent research institution.
Office: Building 152, 11782 River Road, Richmond, B.C. V6X 1Z7 CANADA
Factory: 3521 River Road West, Delta, B.C. V4K 3N2 CANADA
info@oceanixbiotech.com
​
Tel: + 1 604 303 9180
Fax: + 1 604 303 9170
Sign up to Receive News
and Information
Join Us on the Journey
Back to Top
